- Trial phase
- Phase 1 (discontinued)
- Time to market
- Not applicable. CB-011 development has been discontinued and the program terminated (Oct 2026).
- Why 3/10
- CB-011 has been discontinued by Caribou (announced Oct 6, 2026), so there is no upcoming PDUFA or pivotal readout. The next hard catalyst is the ASH 2026 presentation (Dec 12-15, 2026), but it is a data presentation for a terminated program, not a binary regulatory or pivotal event. The real value driver is the corporate strategic alternatives process (potential sale), which has no set date. ImpactScore is low because the drug itself no longer drives a binary outcome.
CB-011 development has been discontinued. The next event is the ASH 2026 presentation (Dec 12-15), but it is a look-back on a terminated program. The real stock-moving catalyst is the strategic alternatives process (potential sale/merger of Caribou), which has no announced timeline. Watch for any acquisition or asset-sale announcement from the company's exploration process.
Price Chart
Executive Summary
CB-011 is an allogeneic (off-the-shelf) anti-BCMA CAR-T cell therapy developed by Caribou Biosciences (CRBU) for relapsed/refractory multiple myeloma. It generated strong Phase 1 CaMMouflage trial data (92% ORR, 75% CR rate in BCMA-naive patients) and received both FDA Fast Track and RMAT designations. However, on October 6, 2026, Caribou announced it would discontinue CB-011 and its other CAR-T program (vispa-cel), cut its workforce, and explore strategic alternatives including a potential sale. The stock fell 35% after hours on the news and now trades around $0.44, down 83% from its 52-week high. ASH 2026 abstracts were accepted for December presentations, but these are look-back data for a terminated program. The drug's development is over; the remaining value lies in Caribou's strategic alternatives process.
How It Works
CB-011 is an allogeneic (off-the-shelf) CAR-T cell therapy that uses CRISPR gene editing to engineer donor immune cells to target BCMA, a protein found on multiple myeloma cancer cells. Unlike approved CAR-T therapies that must be custom-made from each patient's own cells, CB-011 is manufactured from healthy donor cells and can be given to any eligible patient without delay. The CRISPR edits are designed to prevent the donor cells from attacking the patient's body (graft-versus-host disease) and to resist rejection by the patient's immune system.
Trial Status
CB-011 was being evaluated in the Phase 1 CaMMouflage trial (dose escalation and expansion) for relapsed/refractory multiple myeloma. Positive initial data were reported in November 2025, with updated durability data at EHA 2026 (June 2026). The trial was enrolling patients at dose level 1 as of early 2023 and had identified the 450 million cell dose as the recommended dose for expansion. Caribou discontinued the program on October 6, 2026.
The Two-Sided Case
Upcoming Catalysts
- ASH 2026 Annual Meeting (Dec 12-15, 2026): CB-011 clinical data presentation (oral/poster) for a now-discontinued program.
- Strategic alternatives process: potential merger, acquisition, or asset sale with no announced timeline.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Caribou Biosciences, Inc. 8-K CRBU ·Originating report